Why the study?
The study aimed to evaluate the safety and effectiveness of the smallest size balloon-expanding transcatheter heart valve (SAPIEN 3 20 mm) to further refine TAVI procedures.
Does the 20-mm SAPIEN 3 transcatheter heart valve provide comparable 2-year mortality and safety outcomes compared to larger valve sizes in patients with symptomatic severe aortic stenosis?
Does the 20-mm SAPIEN 3 transcatheter heart valve provide comparable 2-year mortality and safety outcomes compared to larger valve sizes in patients with symptomatic severe aortic stenosis?
The 20-mm SAPIEN 3 transcatheter heart valve provides comparable 2-year survival to larger valve sizes in patients with severe aortic stenosis, despite a higher incidence of moderate prosthesis-patient mismatch.
Feasibility of 20 mm SAPIEN 3 supported in selected patients; leaves open durability and comparative efficacy questions.
Objective: Transcatheter aortic valve implantation (TAVI) has become a cornerstone treatment for elderly or high-risk surgical patients with symptomatic severe aortic stenosis. The continuous evolution of TAVI techniques and technology has significantly improved its safety and efficacy. This study aims to deepen our understanding of the safety and effectiveness of the smallest size balloon-expanding transcatheter heart valve (BE-THV): SAPIEN 3 20 mm, through extensive utilization at our institution, with the goal of further refining TAVI procedures in the future.
No takes yet. Share an insight, caveat, or question.
Kataoka et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: